The DOI matches its Crossref record.
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005
Open accessAbstract
Purpose: Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma. Patients and Methods: Eligible patients were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progressed. Patients who were stable or responding to protocol therapy after 2 years had the option to continue with the same blinded therapy. Serial follow-up allowed assessment of efficacy and toxicity. Time to treatment failure and overall survival were ascertained for all randomly assigned patients. On progression, patients receiving placebo could cross over and receive active drug. Results: Among 164 eligible patients, 80 were randomly assigned to mifepristone and 84 to placebo. Twenty-four patients (30%) were able to complete 2 years of mifepristone without disease progression, adverse effects, or other reasons for discontinuation. Twenty-eight patients (33%) in the placebo arm completed the 2-year study. There was no statistical difference between the arms in terms of failure-free or overall survival. Conclusion: Long-term administration of mifepristone was well tolerated but had no impact on patients with unresectable meningioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EANO guidelines for the diagnosis and treatment of meningiomas
Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30321-7 · Cited by 854
EANO guideline on the diagnosis and management of meningiomas
Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab150 · Cited by 742
Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions
Ogasawara, C., Philbrick, B. D., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030319 · Cited by 324
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539
Rogers, L., Zhang, P., Vogelbaum, M. A., Perry, A., Ashby, L. S., Modi, J. M., Alleman, A. M., Galvin, J., Brachman, D., Jenrette, J. M., et al. (2018) · Journal of Neurosurgery · doi:10.3171/2016.11.jns161170 · Cited by 277
Estrogen and progesterone therapy and meningiomas
Hage, M., Plesa, O., Lemaire, I., & Raffin Sanson, M. L. (2022) · Endocrinology · doi:10.1210/endocr/bqab259 · Cited by 63
Metadata
- Authors
- Ji, Y., Rankin, C., Grunberg, S., Sherrod, A. E., Ahmadi, J., Townsend, J. J., Feun, L. G., Fredericks, R. K., Russell, C. A., Kabbinavar, F. F., Stelzer, K. J., Schott, A., & Verschraegen, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-12-01
- Volume
- 33
- Issue
- 34
- Pages
- 4093-4098
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2204645496
- Cited by
- 164
- References
- 0
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.